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Inflammation is associated with many neurodegenerative diseases, including Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. In this Review, we
discuss inducers, sensors, transducers, and effectors of neuroinflammation that contribute to neu-
ronal dysfunction and death. Although inducers of inflammation may be generated in a disease-
specific manner, there is evidence for a remarkable convergence in the mechanisms responsible
for the sensing, transduction, and amplification of inflammatory processes that result in the produc-
tion of neurotoxic mediators. A major unanswered question is whether pharmacological inhibition
of inflammation pathways will be able to safely reverse or slow the course of disease.Introduction
Virchow’s seminal descriptions of activated microglia antici-
pated by more than a century the current interest in roles of
the innate and adaptive immune systems in diverse forms of
neurodegenerative disease. Microglia, a type of glial cell, are
macrophages that are resident in the brain and spinal cord and
form the frontline defense of the innate immune system. Direct
evidence for an innate inflammatory response in Alzheimer’s
disease (AD) was described nearly 20 years ago (reviewed in
Akiyama, 1994), and subsequent studies have documented
inflammatory components in Parkinson’s disease (PD), amyotro-
phic lateral sclerosis (ALS), multiple sclerosis (MS), and a growing
number of other nervous system pathologies. Although inflam-
mation may not typically represent an initiating factor in neurode-
generative disease, there is emerging evidence in animal models
that sustained inflammatory responses involving microglia and
astrocytes contribute to disease progression. A major unre-
solved question is whether inhibition of these responses will be
a safe and effective means of reversing or slowing the course
of disease. To effectively address this question, it will be neces-
sary to learn more about how inflammatory responses are
induced within the central nervous system and the mechanisms
by which these responses ultimately contribute to pathology.
Here, we review studies of the roles of inflammation mediated
by the innate and adaptive immune systems in the pathogenesis
of AD, PD, ALS, and MS and highlight some of the important
areas for future investigation.
Inflammation, Immunity, and Repair
The immune system plays essential roles in the maintenance of
tissue homeostasis and the response to infection and injury.
Microglia are the major resident immune cells in the brain, where
they constantly survey the microenvironment and produce
factors that influence surrounding astrocytes (another type of918 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.glial cell with support functions) and neurons. Under physiolog-
ical conditions, microglia exhibit a deactivated phenotype that
is associated with the production of anti-inflammatory and neu-
rotrophic factors (Streit, 2002). Microglia switch to an activated
phenotype in response to pathogen invasion or tissue damage
and thereby promote an inflammatory response that serves
to further engage the immune system and initiate tissue repair.
In most cases, this response is self-limiting, resolving once infec-
tion has been eradicated or the tissue damage has been
repaired.
Sustained inflammation resulting in tissue pathology implies
persistence of an inflammatory stimulus or a failure in normal
resolution mechanisms. A persistent stimulus may result from
environmental factors or the formation of endogenous factors
(e.g., protein aggregates) that are perceived by the immune sys-
tem as ‘‘stranger’’ or ‘‘danger’’ signals. Inflammatory responses
that establish feed-forward loops may overwhelm normal resolu-
tion mechanisms. Although some inflammatory stimuli induce
beneficial effects (e.g., phagocytosis of debris and apoptotic
cells), and inflammation is linked to tissue repair processes,
uncontrolled inflammation may result in production of neurotoxic
factors that amplify underlying disease states. As a starting point
for comparing and contrasting roles of inflammation in the path-
ogenesis of AD, PD, ALS, and MS, we will first briefly consider
general features of inflammation in the context of innate and
adaptive immunity.
Inducers and Sensors of Infection and Injury
The inflammatory response represents a highly regulated biolog-
ical program that, on the one hand, must enable the innate and
adaptive immune systems to effectively deal with rapidly dividing
microbial pathogens but, on the other hand, involves the produc-
tion of factors that are themselves capable of inducing significant
tissue pathology. As a consequence, genes that play key roles
in amplification or effector functions of inflammatory responses
are actively repressed under normal conditions and are only
induced when cells sense evidence of infection or injury. Inflam-
matory responses to infectious agents are typically initiated by
pattern recognition receptors that bind to so-called pathogen-
associated molecular patterns (stranger signals). One class of
pattern recognition receptor is exemplified by the Toll-like recep-
tors (TLRs), which recognize a diverse set of pathogen-associ-
ated molecules that are not present in the host (see Review
by O. Takeuchi and S. Akira on page 805 of this issue). For
example, TLR4 recognizes lipopolysaccharide (LPS) associated
with gram-negative bacteria, whereas TLR3 recognizes viral
double-stranded RNA. These receptors are expressed on many
cell types but are highly expressed on cells that play central roles
in innate immune responses, including macrophages and micro-
glia. Pattern recognition receptors have more recently been
found to also be capable of responding to endogenously derived
molecules, such as components released from necrotic cells
(danger signals) and by molecules that may be formed as
a consequence of pathogenic mechanisms. Roles of TLR2 and
TLR4 have recently been established in the pathogenesis of
several chronic inflammatory diseases in animal models, and
specific TLR4 polymorphisms are associated with several
human age-related diseases, including atherosclerosis, type 2
diabetes, and rheumatoid arthritis, raising the question of
whether these receptors also contribute to inflammatory pro-
grams associated with neurodegenerative disease (Balistreri
et al., 2009). In addition to pattern recognition receptors, puriner-
gic receptors are expressed on microglia and astrocytes and are
capable of responding to ATP released from cells following cell
death, traumatic injury, or ischemia (Di Virgilio et al., 2009).
Microglia and astrocytes also express a number of so-called
‘‘scavenger receptors’’ that have been demonstrated to be
involved in the uptake of a number of substrates, including
oxidized proteins, lipids, and apoptotic cells, and that may also
contribute to cell signaling (Husemann et al., 2002).
Transduction Systems
Ligation of pattern recognition receptors leads to the activation
of signal transduction pathways that regulate diverse transcrip-
tional and posttranscriptional processes. For example, the
TLRs couple to signaling adaptor systems that are defined by
the MyD88 and TRIF signal adaptor proteins, resulting in activa-
tion of downstream kinases including IkB kinases and MAP
kinases. These in turn control the activities of multiple, signal-
dependent transcription factors that include members of the
NF-kB, AP-1, and interferon regulator factor (IRF) families (see
Review by O. Takeuchi and S. Akira on page 805). These factors
work in a combinatorial manner to regulate hundreds of genes,
depending on the target cell that is activated.
Amplifiers and Effectors
To bring about an effective immune response, the initial detec-
tion of a microbial pathogen must be amplified to recruit addi-
tional cells to sites of infection, induce antimicrobial activities,
and initiate the development of adaptive immunity. Important
subsets of highly induced genes thus include cytokines (e.g.,
TNF-a, IL-1b) that are amplifiers of the program of inflammation
and chemokines (e.g., MCP-1) that serve to recruit additional
immune cells. In addition, genes that encode proteins with anti-
microbial activities (e.g., iNOS) are induced, as are genes thatinfluence substrate metabolism, protein synthesis, cell motility,
phagocytosis, intracellular killing, and antigen presentation.
The generation of reactive oxygen species (ROS), e.g., through
the NADPH oxidase system, is an important antimicrobial mech-
anism but also exemplifies a system that can result in collateral
damage to tissue, e.g., the parenchymal cells in the brain.
Cellular and Tissue Context
Inflammatory responses are typically localized and involve
communication between immune, vascular, and parenchymal
cells. Resident populations of tissue macrophages play key roles
as sentinels of infection and injury but are also increasingly
recognized as having an influence on normal tissue homeo-
stasis. Macrophage phenotypes can be considered in the
context of ‘‘activation’’ status, with M1 or ‘‘classical activation’’
describing the proinflammatory phenotypic response to IFN-g
produced by Th1 T lymphocytes or signaling through TLRs.
M2 or ‘‘alternative activation’’ describes distinct phenotypic
responses to cytokines, such as IL-4 and IL-13, produced by
Th2 lymphocytes and other cell types (see Review by C. Nathan
and A. Ding on page 871 of this issue). The term ‘‘deactivated’’
macrophage has been used to describe phenotypic responses
to anti-inflammatory cytokines, such as IL-10. Transition of
tissue-resident macrophages from the M2 to the M1 phenotype
generally is associated with inflammation-induced pathologies,
such as diet-induced insulin resistance (Lumeng et al., 2007).
As noted above, microglia exhibit a deactivated phenotype in
the healthy brain and may play important roles in maintenance
of tissue homeostasis through communication with astrocytes
and neurons, analogous to homeostatic roles of ‘‘alternatively
activated’’ macrophages in other tissues. The central nervous
system (CNS) is an immunologically privileged site and circu-
lating immune cells normally do not have access to it in the
absence of inflammation or injury. Dendritic cells with special-
ized antigen-presenting capabilities do not appear to be present
under normal conditions. Microglia appear to be the major initial
sensors of danger or stranger signals recognized by TLR4, and
they secrete inflammatory mediators such as TNF-a and IL-1b
that can act on astrocytes to induce secondary inflammatory
responses (Saijo et al., 2009). Microglia are thus likely to play crit-
ical roles in establishing and maintaining inflammatory
responses in the context of neurodegenerative diseases.
Counter-regulation
Numerous negative feedback mechanisms have been identified
that serve to attenuate responses to inducers or amplifiers of
inflammation. These include induction of proteins that inhibit
signal transduction pathways (e.g., SOCS proteins), induction
of transcriptional repressors and transrepressors (e.g., ATF3,
Nurr1), and production of soluble or cell-surface mediators
with anti-inflammatory activities (e.g., IL-10, TGF-b, resolvins,
ligands for TAM receptors). How these negative feedback path-
ways are integrated with proinflammatory signaling pathways to
bring about appropriate resolution of inflammation in any context
remains poorly understood.
Alzheimer’s Disease
Initially described almost 100 years ago by Alois Alzheimer, AD is
one of the most common age-related neurodegenerative dis-
eases, with approximately 7% of people older than 65 yearsCell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 919
and about 40% of people older than 80 years being affected in
industrialized countries. The symptoms of AD are characterized
by loss of memory, progressive impairment of cognition, and
various behavioral and neuropsychiatric disturbances. The path-
ological hallmarks of AD in the brain include extracellular amy-
loid plaques comprising aggregated, cleaved products of the
amyloid precursor protein (APP) and intracellular neurofibrillary
tangles (NFTs) generated by hyperphosphorylated forms of the
microtubule-binding protein tau.
Evidence of an inflammatory response in AD includes changes
in microglia morphology—from ramified (resting) to amoeboid
(active)—and astrogliosis (manifested by an increase in the
number, size, and motility of astrocytes) surrounding the senile
plaques. Moreover, microglia surrounding plaques stain positive
for activation markers and proinflammatory mediators, including
MHC class II, Cox-2, MCP-1, TNF-a, IL-1b, and IL-6 (Akiyama
et al., 2000). MCP-1 is known to induce the chemotaxis of astro-
cytes and contributes to the recruitment of astrocytes around
senile plaques (Wyss-Coray et al., 2003). In addition, elevated
levels of chemokines and cytokines and their receptors,
including IL-1a, CXCR2, CCR3, CCR5, and TGF-b, have been
reported in post-mortem AD brains (Cartier et al., 2005).
Inducers and Sensors of Inflammation in AD
NFTs are composed of hyperphosphorylated forms of the micro-
tubule-binding protein tau, which under normal physiological
conditions regulates cytoskeletal changes. An inflammatory
environment might activate the tau kinases to promote formation
of NFTs (Ballatore et al., 2007), but whether hyperphosphory-
lated tau and NFTs affect inflammatory responses is not yet
well understood.
Senile plaques containing the N-terminal APP cleavage
products Ab1-42 and/or Ab1-40 (Ab) are the hallmarks of AD
pathology. Ab1-42 and Ab1-40 are generated from APP by b-
and g-secretases (Haass and Selkoe, 2007). Rare mutations in
APP and the presenilin components of g-secretase are causes
of familial AD, providing one line of evidence for the hypothesis
that Ab contributes to the pathogenesis of AD (Bertram and
Tanzi, 2008). Although a pathogenic role for Ab is generally
accepted, the mechanisms remain poorly understood. In addi-
tion to numerous cell-autonomous effects in neurons, aggre-
gates of Ab have also been shown to activate microglia and
induce the production of factors, such as nitric oxide (NO),
ROS, proinflammatory cytokines (e.g., TNF-a, IL-1b, IL-6), che-
mokines (e.g., IL-18), and prostaglandins (e.g., PGE2), that
promote neuronal death (Akiyama et al., 2000; Kitazawa et al.,
2004).
Microglia and astrocytes appear to be capable of detecting Ab
through several sensors, including TLRs, that are expressed on
glial cells (Landreth and Reed-Geaghan, 2009). In particular,
Ab has been suggested to activate microglia and astrocytes
through TLR4 (together with CD14 and MD2 in microglia), lead-
ing to the activation of signal-dependent transcription factors
that drive expression of downstream inflammatory response
genes (Reed-Geaghan et al., 2009; Walter et al., 2007). Consis-
tent with this, mice carrying a nonfunctional TLR4 crossed with
a mouse model of AD (APP/PS1 double transgenic mice)
showed production of fewer inflammatory cytokines (Jin et al.,
2008). It has been suggested that TLR4 may participate in the920 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.phagocytosis of Ab plaques by microglia. Indeed, mice carrying
mutant TLR4 crossed with AD transgenic mice exhibited more
Ab plaques (Tahara et al., 2006). A recent report suggests that
Ab fibrils trigger inflammatory responses through TLR4/TLR6 in
the presence of CD36 (Stewart et al., 2009). Intriguingly, a poly-
morphism in the TLR4 extracellular domain has been reported to
be associated with protection against late-onset AD in an Italian
population (Minoretti et al., 2006), suggesting that sterile inflam-
mation could influence AD pathology through TLR4 signaling.
TLR9 stimulation by CpG-DNA (a mimic of bacterial DNA)
showed neuroprotective roles both in vivo and in vitro (Doi
et al., 2009). TLR2 also may be a sensor for fibrillar Ab. Blocking
TLR2 signaling with antibody or by knockdown of the receptor
gene in vitro suggested that TLR2 stimulation by Ab promotes
neurotoxic inflammation. However, mice lacking TLR2 crossed
with APP/PS1 transgenic AD mice were reported to show a delay
in Ab deposition and improved behavior on memory tests (Ri-
chard et al., 2008). These apparently divergent actions of
TLR2, TLR4, and TLR9 in vivo and in vitro are currently difficult
to reconcile but could reflect differences in the specific cell types
that express these receptors as well as differences in the
signaling/effector pathways that are engaged beyond the core
NF-kB response. Sorting out the basis for these differences
will be important.
A second sensing system for Ab is provided by the receptor for
advanced glycoxidation end-products (RAGE), a cell surface
receptor belonging to the immunoglobulin superfamily (Neeper
et al., 1992; Schmidt et al., 1992). RAGE was initially identified
as a receptor for advanced glycoxidation end-products (AGEs).
Pro-oxidant environments, such as an inflammatory milieu, can
promote the production of AGEs that lead to the activation of
RAGE on the surface of microglia, astrocytes, vascular endothe-
lial cells, and neurons. Several reports suggest that Ab peptide
as well as Ab oligomers bind to RAGE and activate glia cells,
especially microglia (Yan et al., 1996). Blocking the interaction
of Ab with RAGE impaired the activation of microglia and
reduced the production of proinflammatory mediators (Ramas-
amy et al., 2009). RAGE is also suggested to play an important
role in the clearance of Ab and to be involved in apoE-mediated
cellular processing and signaling (Bu, 2009). In addition to AGEs
and Ab, RAGE recognizes other ligands including serum amyloid
A (SAA), S100 protein, and high-mobility group box1 (HMGB1).
The increased production of RAGE ligands is often observed in
cellular and organ dysfunction, particularly where inflammation
is involved (Schmidt et al., 2009; Srikanth et al., 2009). These
molecules are often present in the altered tissue environments
associated with type 2 diabetes, and the activation of RAGE
might contribute to the increased risk of AD in patients with
type 2 diabetes.
NOD-like receptors (NLRs) represent a third Ab sensing sys-
tem. NLRs are soluble, cytoplasmic pattern recognition recep-
tors for pathogens and also act as sensors of cellular damage.
(see Reviews by O. Takeuchi and S. Akira on page 805 and
by K. Schroder and J. Tschopp on page 821 of this issue). In
AD, Ab oligomers and fibrils induce lysosomal damage and
trigger NALP3, a member of the NLR family that is expressed
in microglia (Halle et al., 2008). NALPs activate downstream
signaling proteins, such as apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC). Cas-
pase activation by an adaptor ASC induces apoptosis as well
as the maturation of proinflammatory mediators like IL-1b and
IL-18. Also, a lower cellular K+ concentration activates NALP1,
another member of the NLR family that is expressed in neurons.
Similar to NALP3 in glial cells, NALP1 activates ASC and cas-
pases and induces the maturation of IL-1b and IL-18 (see Review
by K. Schroder and J. Tschopp on page 821).
Additional Genetic Factors
As mutations in APP and b- and g-secretases are rare causes of
AD, additional genetic, environmental, and age-related factors
must contribute to the formation of Ab and other events that drive
AD pathogenesis in most individuals. One of the strongest
genetic associations with AD is the E4 allelic variant of apolipo-
protein E (apoE). ApoE is a 34 kDa protein that acts, at least in
part, as a transporter of lipids. In humans, there are three apoE
isoforms: apoE2, apoE3, and apoE4. The apoE4 allele is associ-
ated with an increased risk of AD as well as other neurodegener-
ative and cardiovascular diseases, such as atherosclerosis
(Bu, 2009). Numerous hypotheses have been advanced to
account for these associations (reviewed in Kim et al., 2009),
including differential effects of apoE alleles on inflammation
and Ab processing. In the brain, apoE is mainly produced by
microglia and astrocytes and likely plays many important roles
by binding to members of the low-density lipoprotein (LDL)
receptor family, including the classical LDL receptor (LDLR)
and LDLR-related protein 1 (LRP1) (Jaeger and Pietrzik, 2008).
One recent study suggests that apoE has anti-inflammatory
effects by activating LDLR-mediated signaling. When LDLRs
and LRP1 are stimulated by peptide mimics of apoE, JNK kinase
activity is suppressed and microglia activation is attenuated (Po-
civavsek et al., 2009a, 2009b). This anti-inflammatory effect of
apoE is isoform specific, with apoE4 exhibiting less activity
(Licastro et al., 2007; Vitek et al., 2009). With respect to the roles
of apoE and its receptors in the regulation of APP processing,
LRP1 has been suggested to directly bind to Ab or Ab/apoE
complexes, mediating their uptake by glial cells, which is neuro-
protective (Marzolo and Bu, 2009). In this case, the apoE3/Ab
complex is preferentially taken up by LRP1 compared to the
apoE4/Ab complex. These studies suggest that expression of
the apoE4 protein might result in defects in clearance of Ab
that would promote the deposition of Ab aggregates in the brain,
hence contributing to AD.
Environmental Factors
Many environmental factors may influence inflammatory
responses that contribute to AD pathology, including traumatic
injury, systemic infection, and diet (Migliore and Coppede, 2009).
Traumatic injury activates both microglia and astrocytes and
could potentially induce self-sustaining inflammatory responses
in the brain (Van Den Heuvel et al., 2007). Activation of the
systemic innate immune system by infection may be involved
in the early stages of AD pathogenesis (Perry et al., 2007).
Recently, a strong correlation between type 2 diabetes and AD
has been recognized (Granic et al., 2009; Jones et al., 2009).
Type 2 diabetes with hyperinsulinemia increases the risk of AD
in elderly people (Luchsinger and Gustafson, 2009). Several
different mechanisms have been proposed to explain this corre-
lation. Prolonged consumption of excess calories inducesobesity and a low-grade but chronic form of inflammation in
adipose tissue, liver, and other organs that is associated with
an insulin-resistant state (see Review by G.S. Hotamisligil on
page 900 of this issue). Macrophages are now recognized to
be major sources of proinflammatory mediators that act on
various cell types to impair insulin signaling. It is possible that
systemic inflammation contributing to insulin resistance might
have a direct effect in the brain, or that the activation of tissue
macrophages in type 2 diabetes might reflect an underlying
defect shared by microglia that independently become activated
within the CNS.
Inflammation-Dependent Pathology
Ab formation and associated tauopathy appear to be sufficient to
explain a cell-autonomous stress response in neurons, as
recently supported by studies of the N-APP/DR6 mouse model
of AD (Nikolaev et al., 2009). However, Ab aggregates and prod-
ucts derived from dead cells can trigger microglia and astrocytes
through the TLR and RAGE-dependent pathways, leading to
local inflammation that may further amplify neuronal death
(Figure 1). Although the relative roles of Ab and other potential
initiators of inflammation remain unclear, the activation of
caspases and signal-dependent transcription factors such as
NF-kB and AP-1 results in production of numerous amplifiers
(e.g., IL-1b, TNF-a, IL-6) of inflammation. Proinflammatory cyto-
kines, such as TNF-a, IL-1b, and IL-6, might act directly on
neurons to induce apoptosis (McCoy and Tansey, 2008; Simi
et al., 2007). Furthermore, factors such as TNF-a and IL-1b
released by microglia can activate astrocytes, whereas factors
released from astrocytes may lead to further activation of micro-
glia (Saijo et al., 2009). In addition, APP, presenilin (a component
of g-secretase), and BACE1 (b-secretase) have NF-kB sites in
their promoters, and proinflammatory cytokines are known to
upregulate their expression in neurons (Sastre et al., 2008).
Inflammatory mediators acting on neurons might contribute to
more production of Ab, further activating microglia-mediated
inflammation. Thus, communication between neurons and glia
may amplify the production of neurotoxic factors that contribute
to AD pathology. Region-specific effects on neurons are likely to
depend on the specific types of receptors expressed within
different neuronal populations. For example, TNF-a binds to
TNFR1, which activates cell survival pathways through NF-kB
as well as apoptotic signaling pathways through activation of
caspases. In contrast, TNFRII signaling only activates NF-kB.
Although it is clear that symptoms of AD are caused by neuronal
damage, it is not well understood which neurons are the primary
targets of the neurotoxic process. It was reported that death of
cholinergic neurons in the basal forebrain was an important com-
ponent of AD pathology. However, recent evidence suggests
that other neurons, such as glutaminergic and GABAnergic
neurons, might also be important targets in AD pathology (Riss-
man et al., 2007; Yamin, 2009).
Divergent results have been obtained in attempts to assess
the overall impact of microglia on AD pathology in mice. In one
approach, APP/PS1 transgenic AD mice were crossed to mice
in which microglia, but not macrophages, could be conditionally
depleted. Three weeks after conditional depletion of microglia,
amyloid plaque formation and neuronal damage had not
changed compared to control mice (Grathwohl et al., 2009).Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 921
Figure 1. Inflammation in Alzheimer’s
Disease
Amyloid-b peptide, produced by cleavage of
amyloid precursor protein (APP), forms aggre-
gates that activate microglia, in part by signaling
through Toll-like receptors (TLRs) and RAGE.
These receptors activate the transcription factors
NF-kB and AP-1, which in turn induce the produc-
tion of reactive oxygen species (ROS) and drive
the expression of inflammatory mediators such
as cytokines. These inflammatory factors act
directly on cholinergic neurons and also stimulate
astrocytes, which amplify proinflammatory signals
to induce neurotoxic effects. Apoptosis and
necrosis of neurons result in release of ATP, which
further activates microglia through the purinergic
P2X7 receptor. Microglia can also play protective
roles by mediating clearance of Ab through
ApoE-dependent and ApoE-independent mecha-
nisms. Cholinergic neurons in the basal forebrain,
the neurons that are primarily affected in AD, are
presumed to be important targets of inflamma-
tion-induced toxicity, but other types of neurons,
such as glutaminergic and GABAergic neurons,
may also be affected.Although these results could be interpreted to indicate that mi-
croglia are essentially passive bystanders in AD pathology at
least in this model, the lack of effect of microglia depletion could
also reflect the relatively short timeframe of the experiment or
a balanced reduction in both beneficial and deleterious activities.
A contrasting result was provided by recent experiments in
which the growth factor M-CSF was systemically administered
to APP/PS1 transgenic mice for 4 months. This procedure
resulted in a significant increase in the number of parenchymal
microglia, decreased Ab deposits, and decreased cognitive
loss (Boissonneault et al., 2009), thereby supporting a neuropro-
tective function. The authors suggested that M-CSF injection
primarily resulted in the expansion of bone marrow-derived
microglia. This might provide another explanation for the appar-
ent discrepancy between these results and the data obtained
by selectively depleting microglia resident in the CNS.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurode-
generative disease after AD and is the most common movement
disorder. Currently, about 2% of the population over the age of
60 is affected. Prominent clinical features are motor symptoms
(bradykinesia, tremor, rigidity, and postural instability) and non-
motor-related symptoms (olfactory deficits, autonomic dysfunc-
tion, depression, cognitive deficits, and sleep disorders). Like
AD, PD is a proteinopathy; it is characterized by the accumula-
tion and aggregation of misfolded a-synuclein. Neuropatholog-
ical hallmarks are intracellular inclusions containing a-synuclein
called Lewy bodies and Lewy neurites and the loss of dopami-
nergic neurons in the substantia nigra of the midbrain and in
other brain regions as well (Braak et al., 2003). Loss of dopami-922 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.nergic neurons is not the only neuropathological alteration in PD,
as microglial activation and an increase in astroglia and lympho-
cyte infiltration also occur. An increase in astroglial cells in post-
mortem tissue from the brains of PD patients (Damier et al., 1993)
and an increased number of dystrophic astrocytes (Braak et al.,
2007) have also been reported. Positron emission tomography of
PD patients has shown a marked increase in the peripheral
benzodiazepine receptor expressed by glial cells. Additional
studies are needed to validate the specificity of this imaging
approach, but these findings are suggestive of increased glial
activation in PD patients (Gerhard et al., 2006).
The etiologies of most common forms of PD remain poorly
understood. Originally thought to be a disease characterized
by loss of one neuronal type, PD is now recognized to have an
inflammatory component (Block and Hong, 2007; McGeer and
McGeer, 2008; Nagatsu and Sawada, 2005). Reactive microglia
expressing human leukocyte antigen (HLA)-DR and CD11b,
along with Lewy bodies, are found in the substantia nigra of PD
patients (McGeer et al., 1988). In addition, increased levels of
cytokines in the colony-stimulating factor (CSF) (Nagatsu and
Sawada, 2005) and in the blood have been reported. Although
these inflammatory components are not specific for PD, they
might provide useful biomarkers for monitoring progression of
the disease.
Inducers and Sensors of Inflammation in PD
As is the case for AD, rare mutations in a number of genes cause
familial forms of PD and provide insights into general pathogenic
mechanisms (Gasser, 2009). Among these are mutations in
a-synuclein (PARK1 and PARK4) and DJ-1 (PARK7). a-synuclein
is a 140 amino acid protein that is found physiologically in the
presynaptic terminals of neurons. It plays a major role in PD
neuropathology: a-synuclein aggregates in PD and becomes the
major fibrillar protein in Lewy bodies in both sporadic and
inherited forms of PD. Moreover, point mutations (A53T, A30P,
E46K) and gene multiplications of human wild-type a-synuclein
are related to rare familial autosomal-dominant forms of early-
onset PD. In PD, the aggregation of a-synuclein from monomers,
via oligomeric intermediates, into fibrils is considered the
disease-causing toxic mechanism. Recent reports indicate that
the accumulation of a-synuclein can result in the formation of
intermediate state oligomers, which lead to neuronal cell death
(Danzer et al., 2007). One line of research proposes that neuronal
death itself, including release of protein aggregates, induces
activation of microglia. Additional activation of microglia may
be due to the release of aggregated proteins from neurons into
the extracellular space (Roodveldt et al., 2008). This finding is
interesting, as the a-synuclein-related neuropathological alter-
ations in sporadic PD and in most forms of familial PD were
initially thought to be intracellular. Recent data challenge this
model and indicate the importance of extracellular a-synuclein
aggregates in PD (Lee, 2008). Extracellular a-synuclein is phago-
cytosed by microglia (Zhang et al., 2005), and aggregated,
nitrated, and oxidized forms of a-synuclein have been found to
induce microglial activation (Reynolds et al., 2008; Zhang et al.,
2005). Sensing mechanisms for a-synuclein aggregates are
similar to those for viruses and toxins. Extracellular a-synuclein
is suggested to be sensed and internalized by cell surface gangli-
osides in BV-2 cells (a microglia cell line) in vitro. An important
role has been reported for GM1 gangliosides in endocytosing
a-synuclein, most likely via lipid rafts (Park et al., 2009). a-synu-
clein-mediated neurotoxicity is enhanced by microglial activa-
tion and release of proinflammatory cytokines. The internaliza-
tion of a-synuclein by microglia is followed by activation of
NADPH oxidase and production of ROS (Zhang et al., 2005).
Recently, microglial immunity stimulated by nitrated a-synuclein
was reported to be regulated by CD4+ T regulatory (Treg) cells.
Treg cells may alter the proteome of microglia in response to
nitrated a-synuclein, thereby protecting dopaminergic neurons
(Benner et al., 2008; Reynolds et al., 2008).
A characteristic of dopaminergic neurons in the substantia
nigra is an increase in intracellular oxidative processes related
to the synthesis of dopamine (Kuhn et al., 2006), making them
particularly vulnerable to oxidative stress. In addition, high rates
of catecholamine metabolism drive the production of neurome-
lanin, and high amounts of neuromelanin are suspected to
increase the vulnerability of dopaminergic midbrain neurons to
oxidative stress (Kastner et al., 1992). A direct effect of neurome-
lanin on activation of microglia through activation of NF-kB has
been shown in cultures of rodent microglial cells (Wilms et al.,
2003).
Environmental Factors
As the vast majority of PD cases are sporadic, environmental
factors that interact with common but less penetrant suscepti-
bility genes are likely to influence the onset of most cases of
sporadic PD (Tansey et al., 2007). Although not directly sensed
by microglia, PD-causing toxins are known to induce neuronal
degeneration that is associated with reactive microgliosis, which
exacerbates neurotoxicity. MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) is a neurotoxin that causes permanentsymptoms of PD. Metabolized to 1-methyl-4-phenylpyridinium
(MPP+) by glial cells, MPP+ is taken up by dopaminergic neurons
via the dopamine transporter and induces oxidative stress,
leading to mitochondrial damage and neuronal cell death.
Despite a lack of Lewy bodies in MPTP parkinsonism, activated
microglia were found in patients even 16 years after MPTP expo-
sure. Although these patients may have had further access to
other drugs in the meantime, 18-year-old nonhuman primates
given MPTP years earlier also exhibited activated microglia
and dopaminergic neuronal loss in the absence of Lewy bodies,
suggesting a long-lasting and self-driven reactive microgliosis
(McGeer and McGeer, 2008). The role of bacterial or viral infec-
tion as an initiating factor in human PD is unclear, but intracranial
infusion of bacterial LPS is used as an alternative model for mi-
croglia-induced loss of tyrosine hydroxylase-positive dopami-
nergic neurons in rodents (Castano et al., 1998). LPS-induced
inflammation can also synergize with mutations in a-synuclein
and Parkin that are associated with familial PD to potentiate
the loss of tyrosine hydroxylase-positive neurons in animal
models (Gao et al., 2008). Whether other neuronal populations
are affected remains to be established.
Inflammation-Dependent Pathology
Several lines of evidence suggest that inflammatory mediators
such as ROS, NO, TNF-a, and interleukin (IL)-1b derived from
non-neuronal cells including microglia modulate the progression
of neuronal cell death in PD (Hirsch and Hunot, 2009) (Figure 2).
Evidence that inflammatory responses originating from non-
neuronal cells are sufficient to cause loss of dopaminergic
neurons is provided by studies of LPS-mediated neurotoxity
(Castano et al., 1998). Injection of LPS into the rodent brain
results in increased levels of inflammatory mediators, including
COX-2 and iNOS, prior to loss of dopaminergic neurons (Hunter
et al., 2007). TLR4, the main receptor for LPS, is preferentially
expressed on microglia compared to astrocytes (Kim et al.,
2000), but it is present at very low or undetectable levels on
neurons. Consistent with this finding, microglia are much more
responsive than astrocytes to LPS when assayed in a tissue
culture environment, whereas neurons are virtually unresponsive
(Saijo et al., 2009). Direct application of LPS to neurons has little
effect on gene expression or survival. In contrast, conditioned
media from LPS-treated microglia are neurotoxic, and this effect
is enhanced when conditioned media are added to mixed cul-
tures of astrocytes and neurons. Separation of the different cell
type components of the mixed culture system is most consistent
with the interpretation that microglia are the primary initial
responders to LPS and produce mediators such as TNF-a and
IL-1b that activate astrocytes (Saijo et al., 2009). The combina-
tion of factors that are produced by activated microglia and
astrocytes in turn may promote neurotoxicity. Intriguingly, these
factors are preferentially toxic to dopaminergic neurons, raising
the question of whether differential sensitivity of neurons in PD
is due to factors that are relatively specific to dopaminergic
neurons or whether dopaminergic neurons are more sensitive
to generic neurotoxic factors.
PD-associated, activated microglial cells release NO pro-
duced by iNOS as well as ROS. NADPH oxidase is the major
source of ROS production in activated microglia in PD (Hunot
et al., 1996). A direct effect of a-synuclein on microglia (asCell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 923
Figure 2. Inflammation in Parkinson’s
Disease
Prominent neuropathological hallmarks of Parkin-
son’s disease (PD) are the loss of dopaminergic
neurons in the substantia nigra of the midbrain
and the presence of intracellular inclusions con-
taining aggregates of the a-synuclein protein,
called Lewy bodies. Besides forming Lewy bodies,
aggregates of a-synuclein form intermediate-state
oligomers that when released from neurons acti-
vate microglia through Toll-like receptor (TLR)-
independent mechanisms. This leads to activation
of NF-kB and production of reactive oxygen
species (ROS) and proinflammatory mediators.
These factors act directly on dopaminergic neu-
rons of the substantia nigra, which are the prin-
cipal (although not the only) neurons that die in
PD. These factors also activate microglia, which
amplify the inflammatory response in a positive
feedback loop, leading to further activation of
microglia. Products derived from microglia and
astrocytes act in a combinatorial manner to pro-
mote neurotoxicity. Bacterial lipopolysaccharide
(LPS), acting primarily through TLR4 expressed
by microglia, is sufficient to induce an inflamma-
tory response in the substantia nigra that results
in loss of dopaminergic neurons. The transcription
factor NURR1 acts to suppress inflammatory
responses in microglia and astrocytes by inhibiting
NF-kB target genes.opposed to a TLR-dependent pathway as observed following
LPS treatment) has been demonstrated. Extracellular a-synu-
clein is phagocytosed by microglia, resulting in activation of
NADPH oxidase and ROS production (Zhang et al., 2005).
NADPH oxidase activation and ROS production are a crucial
mechanism for microglia activation after exposure to a-synuclein
as the toxic effect was less strong in mice lacking NADPH
oxidase (Zhang et al., 2005). The oxidative stress-induced nitra-
tion of a-synuclein is a potent inducer of microglial activation
in vitro and in vivo and is associated with activation of NF-
kB-related genes and increased expression of neurotrophins
(NFKB1, TNF, TNFRSF1A, BDNF, GDNF) (Reynolds et al., 2008).
In addition to microglia activation, a recent study using the MPTP
mouse model of PD suggested that infiltration of CD4+ T lympho-
cytes may be involved in PD. Dopaminergic toxicity is mediated
by CD4+ T cells and requires the expression of FasL but not
IFN-g (Benner et al., 2008; Brochard et al., 2009).
Counter-regulation
Mechanisms that act to counter-regulate or resolve inflamma-
tory responses have recently been identified that may be rele-
vant to PD pathology. The chemokine receptor CX3CR1 is pres-
ent on microglia, and CX3CR1 knockout mice show increased
toxicity in response to systemic LPS treatment and augmented
neurodegeneration in the substantia nigra following MPTP
administration (Cardona et al., 2006). A negative feedback
mechanism operating at the level of NF-kB target genes was
recently described for the orphan nuclear receptor Nurr1.
Nurr1 was originally described as being required for the genera-
tion and maintenance of dopaminergic neurons, with rare muta-
tions associated with familial PD. Nurr1 unexpectedly also
inhibits expression of proinflammatory neurotoxic mediators in924 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.microglia and astrocytes. Reduced Nurr1 expression results in
exaggerated inflammatory responses in microglia that are fur-
ther amplified by astrocytes, leading to the production of factors
that cause the death of tyrosine hydroxylase-positive neurons.
Nurr1 exerts anti-inflammatory effects by docking to NF-kB-p65
on target inflammatory gene promoters in a signal-dependent
manner. Subsequently, Nurr1 recruits the CoREST corepressor
complex, resulting in clearance of NF-kB-p65 and transcriptional
repression. These studies suggest that Nurr1 protects against
loss of dopaminergic neurons in PD in part by limiting the
production of neurotoxic mediators by microglia and astrocytes
(Saijo et al., 2009).
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is
a progressive fatal neurodegenerative disease that affects motor
neurons in the brainstem, spinal cord, and motor cortex. The
most common clinical features of ALS were described more
than 150 years ago by the French neurologist, Jean Martin Char-
cot. Clinical features involve degeneration of motor neurons pro-
ducing fasciculation, muscle wasting and weakness, increased
spasticity, and hyper-reflexia. Respiratory complications usually
develop in patients with advanced disease, and the cause of
death is generally paralysis of the respiratory muscles and dia-
phragm. With a projected lifetime risk of 1/2000, ALS is consid-
ered one of the most common motor neuron diseases (Eisen,
2009). ALS is universally fatal, with a median age of onset of
55 years and a survival of 2–5 years after the onset of symptoms.
Although the exact pathophysiological mechanisms underlying
neurodegeneration in ALS remain uncertain, a common patho-
logical hallmark is the presence of ubiquitin-immunoreactive
cytoplasmic inclusions in degenerating neurons, followed by
a strong inflammatory reaction (McGeer and McGeer, 2002).
Prominent neuroinflammation can be readily observed in path-
ologically affected areas of the CNS and in spinal cords from
both human ALS patients and mouse models of the disease
(McGeer and McGeer, 2002). Typically, inflammation in ALS is
characterized by gliosis and the accumulation of large numbers
of activated microglia and astrocytes. Activation of glia in ALS
has been extensively characterized and is marked by elevated
production of potentially cytotoxic molecules such as ROS,
inflammatory mediators such as COX-2, and proinflammatory
cytokines such as IL-1b, TNF-a, and IL-6 (McGeer and McGeer,
2002). Major histocompatibility complex molecules and comple-
ment receptors are highly expressed by reactive microglia in the
primary motor cortex and in the anterior horn of the spinal cords
of ALS patients (McGeer and McGeer, 2002).
Genetically Determined Factors
The majority of ALS cases are sporadic, likely resulting from
a complex gene-gene and gene-environment interplay. Only
10% of the cases are familial. Studies in families with adult-onset
ALS have identified genes responsible for genetic heritability,
such as superoxide dismutase 1 (SOD1) (Rosen et al., 1993),
transactive response (TAR) DNA-binding protein (TARDBP)
(Neumann et al., 2006), and FUS/TLS (fused in sarcoma or
translocation in liposarcoma) (Kwiatkowski et al., 2009; Vance
et al., 2009). Genetically engineered transgenic mouse models
expressing the human SOD1 protein carrying familial ALS muta-
tions recapitulate the disease (Clement et al., 2003). ALS patients
with SOD1 mutations have neuronal inclusions in their motor
neurons that are ubiquitinated. The observation that SOD1
knockout mice have a very mild phenotype and that several
strains with SOD1 mutations still have superoxide dismutase
activity strongly suggests a gain-of-function form of toxicity in
ALS (Turner and Talbot, 2008). The identification of the TAR
DNA-binding protein 43 (TDP-43) as a major component of
ubiquitinated inclusions in sporadic ALS patients and in patients
with another neurodegenerative disease called frontotemporal
lobar degeneration has focused attention on mutations in
TARDBP, the gene that encodes TDP-43 (Neumann et al.,
2006). Recently, dominant mutations in the FUS/TLS gene
were also identified in several ALS families (Kwiatkowski et al.,
2009; Vance et al., 2009). The wild-type FUS/TLS protein
contains RNA-binding motifs and is believed to be involved in
transcriptional regulation (Uranishi et al., 2001; Wang et al.,
2008). Like TDP-43, wild-type FUS/TLS is frequently localized
in the nucleus, but in its mutant form it may exist as aggregates
in the cytoplasm of motor neurons in ALS patients (Kwiatkowski
et al., 2009; Vance et al., 2009). FUS/TLS is a coactivator of
NF-kB, and recent data suggest that it is involved in the inflam-
matory response (Amit et al., 2009; Uranishi et al., 2001).
Sensors and Transduction Systems
Increasing evidence points to receptors of the innate immune
response as potential sensors of molecules that induce or
amplify inflammation in ALS (Letiembre et al., 2009). CD14,
a protein that facilitates TLR4 responses to LPS, and TLR2 are
upregulated in the spinal cords of mice with ALS (Nadeau and
Rivest, 2000; Nguyen et al., 2001) and ALS patients (Letiembre
et al., 2009; Liu et al., 2009). Chronic infusion of a presymptom-atic ALS mouse with LPS enhanced the innate immune response
and also exacerbated disease progression (Nguyen et al., 2004).
Microglia expressing mutant SOD1 exhibited an increase in
NADPH oxidase-dependent production of ROS (Liu et al.,
2009). Furthermore, the oxidation boost was followed by an
increase in secretion of TNF-a and the metalloproteinases
ADAM10–17, reinforcing a potential link between oxidative
stress and inflammatory responses in ALS. Extracellular mutant
SOD1 can also induce microglial activation via the MyD88-
dependent pathway. This was shown by injecting mutant SOD1
protein into the brains of normal or MyD88/ mice and
observing that a proinflammatory response was only induced
(measured by expression of TLR2 and IL-1b) in the brains of
wild-type animals (Kang and Rivest, 2007). Interestingly, this
inflammatory response was associated with infiltration of brain
tissue by bone marrow-derived microglia (or macrophages);
reconstitution of the hematopoietic system of SOD1G37R mutant
mice with MyD88-deficient cells resulted in earlier disease onset
and a shortened life span. These findings point to potential
neuroprotective mechanisms in which bone marrow-derived
myeloid cells eliminate secreted mutant SOD1 protein, perhaps
analogous to the role of bone marrow-derived microglia in the
clearance of Ab (Boissonneault et al., 2009). An increase in cell
death-associated extracellular ATP in the spinal cords of ALS
patients may induce the purinergic receptor (P2X7) expressed
by microglia to release IL-1b (Yiangou et al., 2006). It is possible
that dying neurons in ALS patients may release ATP and, in turn,
promote activation of glial cells. The principal transcription
factors involved in regulating the expression of genes respon-
sible for production of potential neurotoxic molecules remain
to be established. Based on the suggested roles of TLRs and
purinergic receptors as sensing systems, candidate transcrip-
tion factors include AP-1 and NF-kB, but further investigation
is required.
Inflammation in ALS Pathogenesis
The major determinants of motor neuron death in ALS remain to
be established. Although IL-1b and TNF-a are neurotoxic in vitro,
deletion of either gene alone did not alter disease progression in
SOD1 mutant mice (Gowing et al., 2006; Nguyen et al., 2001).
Although it is possible that IL-1 and TNF-a are not important
contributors to in vivo pathology, an alternative interpretation is
that motor neuron death in ALS is the consequence of multiple
factors acting in a redundant manner. In this scenario, loss of
a single effector molecule is not sufficient to alter the disease
phenotype. Consistent with this possibility, administration of
the anti-inflammatory drug lenalidomide extended survival of
SOD1 mutant mice and improved motor behavior even after
the onset of symptoms; these improvements correlated with
the reduced expression of TNF-a, IL-1b, and FasL (Neymotin
et al., 2009). A motor neuron-specific death pathway has been
suggested for ALS based on the finding that motor neurons
isolated from transgenic SOD1 mutant mice were more sensitive
to Fas- or NO-triggered cell death than wild-type motor neurons
(Raoul et al., 2002). Upon binding of FasL to the Fas receptor, the
intracellular portion of Fas recruits the adaptor molecule FADD,
which then activates a caspase cascade that culminates in
the death of motor neurons. This pathway was also activated
in presymptomatic ALS mice (Raoul et al., 2006). Given thatCell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 925
Figure 3. Inflammation in Amyotrophic
Lateral Sclerosis
The pathology of amyotrophic lateral sclerosis
(ALS) is characterized by degeneration of motor
neurons. Familial ALS is caused by mutations in
the SOD1 gene, but the genes mutated in sporadic
ALS are not yet defined. Progressive neurodegen-
eration of motor neurons in ALS may result
from a combination of intrinsic motor neuron
vulnerability to aggregates of mutant SOD1 pro-
tein and non-cell-autonomous toxicity exerted by
neighboring cells. Toxic aggregates can induce
inflammatory responses by microglia via Toll-like
receptor 2 (TLR2) and CD14. Microglia can induce
astrocyte activation by producing cytokines. Acti-
vated microglia and astrocytes amplify the initial
damage to the motor neurons by activating AP-1
and NF-kB through production of proinflammatory
cytokines and apoptosis-triggering molecules
such as TNF-a and FASL. TNF-a and IL-1b exert
neurotoxic effects in vitro, but deletion of the indi-
vidual genes does not affect the course of the
disease in an animal model. Dying motor neurons
release ATP that can further activate microglia
through the purinergic receptor P2X7 expressed
by microglia.astrocytes and microglia produce NO and that astrocytes
from SOD1 mutant mice produce FasL (Barbeito et al., 2004),
glial cells could be the executioners that directly kill motor
neurons. Another member of the same receptor family, the p75
neurotrophin receptor, has also been implicated in ALS-depen-
dent motor neuron death (Pehar et al., 2004). Specifically, nerve
growth factor secreted by SOD1 mutant astrocytes induced
the death of motor neurons expressing p75 by a mechanism
involving the formation of NO and peroxide (Pehar et al., 2004).
Even though motor neurons are the main cells affected in
ALS, increasing evidence points to the involvement of neigh-
boring glia cells during pathogenesis (Figure 3) (Clement et al.,
2003; Yamanaka et al., 2008b). Cell-specific deletion of mutant
SOD1 in astrocytes and microglia using GFAP-Cre or CD11b-
Cre transgenes, respectively, reduced disease severity and
boosted the survival of ALS mice (Boillee et al., 2006; Yamanaka
et al., 2008b). Although there are some concerns related to the
timing and efficiency of Cre-mediated excision in these experi-
ments, evidence for a role for non-neuronal cells has been
obtained using chimeric mice selectively expressing SOD1 in
neurons or in non-neuronal cells (Yamanaka et al., 2008a). In
chimeric mice expressing high levels of mutant SOD1 in 100%
of motor neurons and oligodendrocytes, the presence of wild-
type neighboring support cells substantially delayed the onset
of motor neuron degeneration. We and others have shown that
glial cells expressing various mutant forms of SOD1 can exert
toxic effects on healthy (nonmutated) human motor neurons
when cocultured with them in vitro (Di Giorgio et al., 2008; Mar-
chetto et al., 2008). Gene expression profiling implies that inflam-
matory cascades are activated before the initiation of motor
neuron degeneration, suggesting that inflammation could be
involved in the presymptomatic phase of the disease (Vargas
et al., 2008). Mutant SOD1, but not the wild-type protein, has926 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.been proposed to be secreted into the extracellular space via
chromogranin vesicles, causing activation of microglia and re-
sulting in motor neuron death in culture (Urushitani et al.,
2006). Consistently, mutant SOD1 is present in the cerebrospinal
fluid of ALS patients and it is toxic to rodent spinal cord cultures
(Tikka et al., 2002). Moreover, intracerebral infusion of mutant
SOD1 into wild-type mice induced microglial activation and
cytokine production (Kang and Rivest, 2007). Although there is
no evidence for direct binding, mutant SOD1 in the extracellular
space could be a ligand that sensor molecules detect resulting in
activation of the inflammatory response. In the case of mutations
in TARDBP and FUS/TLS and in sporadic forms of ALS, it is still
not clear which molecules are responsible for triggering of the
immune response. One could speculate that misfolded, ubiquiti-
nated proteins may play a role. The initial inflammatory reaction
could also come from extracellular ATP released by injured
neurons, which is sensed by purinergic receptors on glia (Yian-
gou et al., 2006).
Emerging evidence points to an involvement of the adaptive
immune response in ALS disease progression. An increase in
IL-12 has been found in the brains of SOD1 mutant mice that
have been chronically treated with LPS (Nguyen et al., 2004).
IL-12 is a cytokine involved in the transition from the innate to
the adaptive immune response that promotes the differentiation
of CD4+ lymphocytes into IFN-g-producing Th1 helper cells (see
Review by O. Takeuchi and S. Akira on page 805). Indeed,
increased levels of CD4+ and CD8+ T lymphocytes and dendritic
cells were detected in close proximity to dying motor neurons in
the spinal cords of SOD1 mutant mice and in the brain paren-
chyma of ALS patients (Mantovani et al., 2009). The role of infil-
trating T lymphocytes in ALS pathology is not yet clear, but
recent reports suggest that they may have a neuroprotective
function (Banerjee et al., 2008; Beers et al., 2008; Chiu et al.,
2008). In fact, it has recently been proposed that infiltrating
T cells (Th2) can be neuroprotective after secreting IL-4, which
signals reactive microglia to produce neurotrophic factors such
as insulin growth factor (IGF1) (Chiu et al., 2008).
Multiple Sclerosis
Multiple sclerosis (MS) is a heterogeneous and complex autoim-
mune disease that is characterized by inflammation, demyelin-
ation, and axon degeneration in the CNS. This pathology results
from a primary defect in the immune system that targets compo-
nents of the myelin sheath, resulting in secondary effects on
neurons. Thus, in contrast to AD, PD, and ALS, protein aggre-
gates are not pathogenic factors. The manifestations of MS
include defects in sensation and in the motor, autonomic, visual,
and cognitive systems. MS predominantly affects young adults
and 2–3 times more females than males. In the early stage of
the disease, approximately 85% of MS patients show the
relapse-remission type of disease. However, with time, the
recovery of these relapsing-remitting patients is impaired and
eventually leads to irreversible progression, that is, secondary
progressive MS. The majority of relapsing-remitting MS patients
progress to secondary progressive MS. In contrast, about 10%
of MS patients do not show any remission, and the primary
neurological symptoms exhibit continuous so-called primary
progression (Goverman, 2009; Sospedra and Martin, 2005).
MS lesions are characterized by infiltration of lymphocytes
and antibody-producing plasma cells into the perivascular
region of the brain and spinal cord white matter, an increase in
microglia and astrocytes, and demyelination (Lassmann et al.,
2001). The deposition of antibodies and complement around
demyelinated lesions (Frohman et al., 2006) and axonal degener-
ation in the progression phase of MS have also been observed
(Trapp and Nave, 2008). When damage and the ensuing inflam-
matory response are transient, remyelination of nerves can take
place as part of normal repair. However, in the presence of
chronic inflammation, such as in MS, remyelination is severely
impaired and leads to axon degeneration and the eventual
demise of the neuron.
Initiators and Sensors of MS
In contrast to AD, PD, and ALS, there is no clear familial form of
MS that could help to identify endogenous initiators of disease.
The development of MS is generally thought to require a combi-
nation of environmental factors acting on genetic traits that ulti-
mately lead to an autoimmune response that targets the myelin
sheath surrounding nerves. Experimental autoimmune encepha-
lomyelitis (EAE), in which rodents are immunized with a myelin-
derived antigen and adjuvant, is the most common animal model
of MS. By varying the genetic background and immunization
protocol, EAE can reproduce the symptoms of the major forms
of human MS.
Viral and bacterial infections are strong candidates for factors
that could initiate MS because regions of pathogen-associated
proteins resemble myelin proteins, such as myelin basic protein
(MBP), and are antigenic. For example, a peptide from hepatitis
B virus (HBV), which is known to be associated with MS, is struc-
turally very similar to a peptide derived from MBP when pre-
sented in the context of MHC molecules by antigen-presenting
immune cells such as dendritic cells (Sospedra and Martin,2005). In combination with other factors, HBV infection provokes
MS by activating T cells that respond to the HBV peptide antigen
and the MBP peptide (Fujinami and Oldstone, 1985), suggesting
the possibility that molecular mimicry may underlie the targeting
of the adaptive immune system to specific myelin components.
Other common pathogens, such as Epstein-Barr virus and
some enterobacteria, have also been associated with the onset
of MS (Lang et al., 2002), although the critical antigens have not
been defined.
Both the innate and acquired immune systems are involved in
MS pathology. Several lines of evidence demonstrate that
immune cells outside of the CNS such as dendritic cells are
key players in MS pathogenesis (Bailey et al., 2007; Figure 4
shows a simplified view of MS pathogenesis within the CNS).
Although autoreactive T and B cells play major roles in MS
pathology, it is the innate immune system that initiates the dis-
ease. For example, naive T cells recognize the myelin-specific
antigen MBP when this autoantigen is presented in the context
of MHC by antigen-presenting cells such as dendritic cells,
macrophages, and microglia. Antigen-presenting cells not only
present the antigen to T lymphocytes but also provide costimu-
lation and produce the cytokines required for T cells to differen-
tiate into effector cells.
TLRs are expressed by antigen-presenting cells and astro-
cytes. Triggering such receptors will affect the differentiation
and activation of T cells. Somewhat surprisingly, the Asp299Gly
polymorphism in TLR4, which is associated with susceptibility to
type 2 diabetes, is not associated with susceptibility to MS
(Kroner et al., 2005). The functions of TLRs in mouse models of
MS are complex, with both stimulatory and protective roles iden-
tified. These observations can be explained by the responses of
innate immune cells and their influence on the differentiation of
distinct subsets of T helper cells (Marta et al., 2009). Recently,
phagocytosis of infected apoptotic cells (which trigger TLR
signaling) was reported to be a physiological signal that induces
activation of effector T cells in vivo (Torchinsky et al., 2009).
Autoreactive T and B lymphocytes play roles as amplifiers and
effectors in MS. Th1 helper T cells were initially thought to play
a crucial role in MS pathogenesis. However, characterization of
specific functions of IL-12, IL-23, and other IL-12 family members
has uncovered essential roles for a subset of T helper cells called
Th17 cells in the pathogenesis of MS (Cua et al., 2003). These
Th17 cells secrete members of the IL-17 proinflammatory cyto-
kine family, especially IL-17A and IL-17F (Korn et al., 2009), and
play a key role in infection by pathogens and in gut immunity
(see Review by D.R. Littman and A.Y. Rudensky on page 845 of
this issue). The differentiation and activation of Th17 cells
requires signaling though the T cell receptor (TCR) as well as
a mixture of cytokines produced by antigen-presenting cells.
These include IL-1b for human and IL-6 for mice, and TGF-b as
well as IL-23 and other cytokines. Th17 cells also secrete IL-21,
which induces activation of Th17 cells in an autocrine manner
(Korn et al., 2009). The retinoic acid receptor-related orphan
receptor gt (RORgt) plays a key role in Th17 cell differentiation.
Treg cells, which are anti-inflammatory helper T cells, play an
opposing role by inhibiting the activity of Th17 cells. Differentia-
tion of this cell type requires the Foxp3 transcription factor (see
Review by D.R. Littman and A.Y. Rudensky on page 845).Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 927
Figure 4. Inflammation in Multiple Sclerosis
Infection by bacteria or viruses or other environ-
mental stimuli trigger the activation of microglia
and astrocytes in multiple sclerosis (MS), leading
to the production of proinflammatory cytokines
through activation of the transcription factors
NF-kB and AP-1. Naive T cells recognize myelin-
derived antigen presented in the context of MHC
molecules by antigen-presenting cells. In the pres-
ence of IL-6 and TGF-b, the naı¨ve T cells are
induced to express retinoic acid receptor-related
orphan receptor gt (RORgt) and differentiate into
Th17 cells. Activated microglia and astrocytes
secrete IL-23 and osteopontin, which induce
Th17 cells to secrete IL-17 and TNF-a resulting
in damage to the myelin sheath that protects nerve
axons. Activated astrocytes produce BAFF, a
survival factor for autoreactive B cells, which dif-
ferentiate into plasma cells and produce anti-
myelin antibodies. Activated microglia and astro-
cytes are also sources of reactive oxygen species
(ROS) and nitric oxide (NO), which contribute to
the destruction of the myelin sheath and of the
neurons themselves. Regulatory T cells (Treg)
that express Foxp3 suppress the activity of Th17
cells and thus help to suppress inflammation.Although MS is recognized as a noninherited disease, there
are many polymorphisms reported to influence susceptibility
to MS. In particular, MHC haplotype is an important determinant
of susceptibility to MS. In the human, the HLA-DR/DQ haplotype
and the HLA-A3 and HLA-B7 haplotype are known to influence
the susceptibility to or protection from MS among certain
populations (for reviews, see Fugger et al., 2009). Additional
factors that influence risk include polymorphisms in the T cell
receptor b chain (TCR-b), CTLA4, TNF-a, ICAM1, CCR5, IL-10,
IL-4R a chain, IL-2R b chain, IL-7R a chain, IFN-g, CD6, IRF8,
TNFSF1A (TNFRI), vitamin D receptor, and the estrogen
receptor (Fugger et al., 2009). Genome-wide association studies
have identified additional loci on chromosomes 17, 5, and 19,
and a recent large genetic study identified more MS-susceptible
loci on chromosomes 12 and 20, for which the responsible
genes need to be determined (ANZgene, 2009; see Essay by
Zenewicz et al. in this issue). Many of the candidate genes
residing within these loci are expressed in T and B lymphocytes
and regulate the differentiation, activation, and migration of
effector T and B cells, consistent with their potential influence
on MS pathogenesis.
Relapse and Remission
Relapse and remission are among the characteristic features
of MS. What triggers the relapse of MS is not fully understood,
but activation of the innate immune system, for example by
infection, is one reported cause (Sospedra and Martin, 2005).
Deregulation of immunity by memory T and B cells might be
another cause of relapse. a4b1-integrin (VLA4) is an adhesion
molecule expressed by T cells that allows autoreactive T cells
to break through the blood brain barrier and migrate into the
brain parenchyma; thus, one therapeutic strategy is to block
VLA4 signaling using monoclonal antibodies (Yednock et al.,
1992). Osteopontin is a cytokine secreted by activated microglia,
astrocytes, and neurons that binds to VLA4, stimulating the928 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.production of proinflammatory cytokines and blocking apo-
ptosis of autoreactive T cells. These two molecules may co-
operate to induce relapse in the CNS in MS (Hur et al., 2007).
With respect to remission, ab-crystallin mRNA has been identi-
fied as the most abundant mRNA in MS lesions. Mice lacking
ab-crystallin exhibit exacerbated symptoms of MS, and adminis-
tration of recombinant ab-crystallin improves the symptoms of
relapsing-remitting MS and secondary progressive MS in animal
models (Ousman et al., 2007).
Neuroinflammation: Common and Disease-Specific
Features
Viewed from the perspective of inducers, sensors, transducers,
and effectors, each of the neurodegenerative diseases consid-
ered here is distinguished by a disease-specific mechanism for
induction of inflammatory responses. The distinct pathways for
production of inducers of inflammation—such as Ab, a-synu-
clein, mutant SOD1, and myelin peptide mimetic—and the
specific anatomical locations at which these processes occur
are likely determinants of the specific pathologicial features of
each disease. Remarkably, however, once inducers are gener-
ated, there appears to be considerable convergence in the
sensor, transducer, and effector mechanisms that lead to ampli-
fication of inflammatory responses, neurotoxicity, and neuronal
death. Activation of innate immune cells in the CNS, such as
microglia and astrocytes, is one of the universal components
of neuroinflammation (Figures 1–4). In particular, TLRs and other
pattern recognition receptors expressed on microglia are likely
to play significant roles in initiating inflammatory responses
that are further amplified by astrocytes. Similarly, signal trans-
duction pathways downstream of these receptors that regulate
the activities of the transcription factors NF-kB and AP-1 appear
to play general roles in mediating the production of amplifiers
and effector molecules, such as cytokines (e.g., TNF-a, IL-1b,
Table 1. Therapeutic Targets for Treating Neuroinflammation
Target Disease Agent Study Status
Inducers Ab AD Tarenflurbil Phase III No benefit
Sensors RAGE AD PF-04494700 Phase II Ongoing
Transducers PPARg AD Rosiglitazone Phase II Improved cognition
MLK PD CEP-1347 Phase III No benefit
Effectors Cox-2 AD; ALS Celecoxib Phase III; phase II/III No benefit; no benefit
Cox-2 ALS Nimesulide Phase I Ongoing
ROS AD; ALS Vitamin E+selenium; Vitamin E Phase III Ongoing; no benefit
ROS AD; ALS CoenzymeQ Phase III; phase II Ongoing; no benefit
ROS ALS Celastrol Phase I Ongoing
Cells Microglia PD; ALS Minocycline Phase II; phase III Ongoing; no Benefit
Leukocytes MS Alemtuzumab Phase III Improvement
Astrocytes ALS ONO-2506 Phase III Ongoingand IL-6), ROS, and NO. Several of these factors could be
general neurotoxic factors for all of the neurodegenerative
diseases discussed above. However, the marked involvement
of the adaptive immune system clearly distinguishes MS from
AD, PD, and ALS, although T cells do seem to play a neuropro-
tective role in ALS.
It is likely that sustained inflammatory responses that con-
tribute to neurodegeneration are driven, at least in part, by
positive feedback loops. Crosstalk between microglia and astro-
cytes is predicted to lead to amplification of inflammation and
release of ATP by necrotic neurons that would be expected to
activate microglia in each of the disease contexts considered
here. Such feedback loops could, in principle, become indepen-
dent of the original inducing molecules that are required to
initiate inflammatory responses. In addition, inflammation may
itself influence the production of disease-specific inducers,
such as Ab.
It will be interesting to determine how the output of activated,
innate immune cells affects specific types of neurons. For
example, many of the same cytokines are suggested to play
pathological roles in AD, PD, and ALS, but the patterns of
neuronal loss are distinct. It will therefore be important to deter-
mine whether this difference reflects different sensitivities of
specific neurons to generic neurotoxic factors or the production
of neurotoxic factors with neuron-specific activities. Finally,
much more effort will be required to understand the gene net-
works that underlie the neuroprotective roles for microglia and
astrocytes, and how these networks are perturbed in chronic
disease states.
Therapeutic Implications
A major unanswered question is whether it will be possible to
safely and effectively target inflammatory mechanisms that con-
tribute to the pathogenesis of AD, PD, ALS, and MS. Table 1
lists examples of therapeutic approaches that have been tested,
are in clinical trials, or are currently being developed that directly
or indirectly influence inflammatory responses. Notable progress
has been made in the case of MS, where the function of the
adaptive immune system can be altered with therapeutic anti-
bodies against key cell surface antigens. For example, basedon the contribution of B cells to MS pathology, a monoclonal
antibody (rituximab) that depletes memory B cells has been
investigated as a potential therapeutic strategy (Dalakas, 2008).
Although clinically effective, this treatment carries a risk of
progressive multifocal leukoencephalopathy, a rare but highly
adverse side effect. Indeed, most of the biological agents
currently being evaluated in MS carry some risk of eliciting auto-
immunity, and effective and safe therapies remain elusive.
In the cases of AD, PD, ALS, and other neurodegenerative
diseases in which microglia and astrocytes are the primary
contributors to inflammation, therapeutic approaches logically
would aim to modulate the sensor/transducer/effector functions
of the innate immune system, that is, TLRs, NF-kB, and TNF-a,
respectively. These approaches also face numerous challenges
with respect to timing, efficacy, and safety. Epidemiological
studies suggest that cyclooxygenase inhibitors reduce the risk
of PD and AD (reviewed by Choi et al., 2009), but clinical trials
of these agents in patients with manifest disease have failed in
AD (Aisen et al., 2003; Reines et al., 2004) and ALS (Cudkowicz
et al., 2006). In concert with studies in animal models, these
findings suggest that targeting inflammatory pathways might
be more effective in preventing disease progression than in
reversing existing pathology. If so, the application of these strat-
egies might require identification and treatment of high-risk
patients prior to the development of overt or severe symptoms.
Biomarkers of subclinical pathology would thus be of great utility
for identifying at risk patients and for monitoring the efficacy of
treatments.
To be clinically effective, anti-inflammatory therapies will have
to gain access to the CNS and target specific cells and pathways
that are quantitatively important in disease pathogenesis in
humans. Animal models and cellular assays are useful for
defining key pathways and neurotoxic factors for specific types
of neurons but should be tuned as much as possible to contexts
that are representative of human disease. An important case in
point is provided by the anti-inflammatory drug minocycline,
which delayed disease progression in an ALS transgenic mouse
model but worsened disease symptoms in phase III clinical trials
in ALS patients (Gordon et al., 2007; Kriz et al., 2002), suggesting
that the transgenic model is a weak representation of sporadicCell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc. 929
ALS. The recent demonstration that induced pluripotent stem
(iPS) cells derived from ALS patients can be differentiated into
astrocytes and specific types of neurons represents an impor-
tant advance for developing in vitro humanized systems for
mechanistic studies and evaluation of therapeutic agents (Dimos
et al., 2008; Ebert et al., 2009). In addition to looking at neurons
as endpoints, these systems may also facilitate efforts to define
the genetic programs that underlie the neuroprotective as well
as the neurotoxic functions of microglia and astrocytes and to
therapeutically modulate these genetic programs.
As AD, PD, and ALS are chronic degenerative diseases, it is
likely that their prevention and treatment will require long-term
therapy, imposing a corresponding requirement for a high level
of safety. The major obvious risks are in suppressing innate
immune function to the point of enabling opportunistic infec-
tions. Based on the broad range of anti-inflammatory therapies
that are in clinical use for systemic inflammation that do not
compromise innate immune function, selectivity should be
possible. An interesting case in point is provided by the thiazoli-
dinedione class of drugs that are ligands for PPARg and are used
in the treatment of type 2 diabetes. These drugs regulate lipid
and glucose metabolism and suppress inflammatory responses
by macrophages and microglia (Tontonoz and Spiegelman,
2008). Recent studies suggest that these drugs have preventive
activity in AD (Risner et al., 2006; Watson et al., 2005). Although
currently available PPARg agonists have a number of unwanted
side effects, they are not associated with suppression of immu-
nity. Furthermore, due to the complex nature of these diseases
and the number of cell types involved, it may take more than
one drug to confer a therapeutic benefit. This approach will
require a new clinical trial design, exemplified by a recent phase
II randomized trial of a celecoxib and creatine (a COX-2 inhibitor
and antioxidant) combination therapy in ALS patients (Gordon
et al., 2008).
Finally, recent developments in embryonic stem cell and iPS
cell technologies are facilitating efforts to replace damaged
neurons in a variety of neurodegenerative diseases. However,
if cultured neurons are engrafted into regions of the brain in
which there is persistent inflammation, then they will be exposed
to a neurotoxic environment and it may be difficult to achieve
a beneficial clinical outcome. It is thus possible that inhibition
of inflammation may also be a prerequisite for successful cell
replacement therapy.
Conclusion
Neurodegenerative diseases, exemplified by AD, PD, ALS, and
MS, represent major unmet challenges for therapeutic interven-
tions. Characterization and targeting of the processes that
initiate specific disease pathologies and act primarily at the level
of neurons are clearly important areas for continued investiga-
tion. The emerging evidence for both protective and pathogenic
roles of microglia and astrocytes and the activation of common
inflammation pathways in these cells in several neurodegenera-
tive diseases supports the concept that glia-induced inflamma-
tion is an amplifier of pathology. Although inhibition of neuroin-
flammation may not alter the underlying cause of disease, it
may reduce the production of factors that contribute to neuro-
toxicity, thereby resulting in clinical benefit. Further knowledge930 Cell 140, 918–934, March 19, 2010 ª2010 Elsevier Inc.of the inducers, sensors, transducers, and effectors of neuroin-
flammation may make attainment of this goal possible.
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